Page last updated: 2024-12-06

diltiazem hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diltiazem hydrochloride is a calcium channel blocker used to treat high blood pressure, angina, and some types of irregular heartbeat. It works by relaxing the blood vessels and slowing down the heart rate. Diltiazem hydrochloride is typically taken by mouth, but it can also be given intravenously. It is available as a generic drug. Diltiazem hydrochloride is studied because it is an effective treatment for various cardiovascular conditions. It has been shown to reduce the risk of heart attacks, strokes, and other cardiovascular events. Research is ongoing to explore the use of diltiazem hydrochloride for other conditions, such as migraines and cancer. Diltiazem hydrochloride is synthesized by a multi-step process that involves several chemical reactions. The synthesis of diltiazem hydrochloride is complex and requires specialized equipment and expertise. Diltiazem hydrochloride is a prescription drug and should be taken only as directed by a doctor.'

Carex: fluoride (1.8%) containing varnish; no further information available 8/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Carexgenusfluoride (1.8%) containing varnish; no further information available 8/91[MeSH]CyperaceaeThe sedge plant family of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons)[MeSH]

Cross-References

ID SourceID
PubMed CID62920
CHEMBL ID1697
CHEBI ID645509
SCHEMBL ID15457
MeSH IDM0353529

Synonyms (309)

Synonym
chebi:645509 ,
AC-15189
(+)-5-(2-(dimethylamino)ethyl)-cis-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one acetate ester monohydrochloride
acetic acid (2s,3s)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; hydrochloride
2-[(2s,3s)-3-(acetyloxy)-2-(4-methoxyphenyl)-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2h)-yl]-n,n-dimethylethanaminium chloride
MLS001148257
smr000058375
MLS000028432 ,
EU-0100327
(+)-cis-diltiazem hydrochloride, >=99% (hplc)
dilem
diltiazem chloridrate
corazet
tazem
dilfar
dilatam 120
dyalac
dilso
diltiazem merck
cardizem cd
levozem
herbesser 90 sr
cartia xt
tilazem
crd-401
zilden
dilzene
tildiem la
longazem
etizen
diladel
angitil
dilicardin
gadoserin
britiazim
lacerol
herbesser
viazem xl
deltazen
anginyl
diatal
einecs 251-443-3
cardiazem
dodexen
mono-tildiem
syn-diltiazem
(2s-cis)-3-acetoxy-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one monohydrochloride
dinisor retard
dilcard
tildiem
entrydil
cardizem sr
herbesser 60
dilzem rr
dilacor xr extended release capsules
zildem
kardil
diltiazem msd
diltiasyn
tildiem retard
diltiazem basics
dilzicardin
diltahexal
apo-diltiazem
dilsal
tilazem 90
slozen
altiazem retard
myonil retard
lytelsen
coras
farmabes
dilatame
tiaves
tiazac
myonil
dilren
presoken
diltiazem-mepha
poltiazem
dilzem
metazem
viazem sr
trumsal
citizen
cirilen ap
1,5-benzothiazepin-4(5h)-one, 2,3-dihydro-3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-, monohydrochloride, cis-(+)-
iski
diltiazem verla
masdil
oxycardil
ubicor
pentilzeno
cardizem retard
novo-diltazem
tilazem as 90
diltiazem-isis
calnurs
diltiazem-gry
(+)-5-(2-(dimethylamino)ethyl)-cis-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one acetate (ester) monohydrochloride
diltam
diltan
diltiazem henning
rg 83606
cirilen
diltiazem eu rho
cardil retard
bruzem
etyzen
diltan sr
diltiazem awd
hart
diltelan
cardil
cardizem
uni masdil
diltikor
diltiazem-cophar
diltiazem stada
helsibon
dilpral
angizem
ziruvate
carex
dazil
tildiem cr
bi-tildiem
cardizem la
pazeadin
adizem-cd
dinisor
dilgard
kaltiazen
miocardie
dilatam
herben
wl diltiazem
clarute
tiadil
diltiazem upsa
diltiazem hcl
iski-90 sr
dilrene
carzem
dil-sonaramia
diltiazem gnr
altiazem rr
incoril
diltime
hesor
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (+)-cis-
tilazem as 60
altiazem
taztia xt
doclis
dilzem retard
calcicard
dilzereal 90 retard
herbesser 180 sr
PRESTWICK_176
diltiazem hydrochloride
33286-22-5
BIM-0050315.0001
D00616
cartia xt (tn)
cardizem (tn)
dilacor xr (tn)
dilt-cd (tn)
diltiazem hydrochloride (jp17/usp)
(+)-cis-diltiazem hydrochloride
bnp-32762
adizem
milptin
ven-307
uni-masdil
slozem
tiazac xc
carzen
cardizem xl
slv-324
NCGC00093768-01
dov diltiazem
dilacor
crd401
crd 401
MLS002222179
D 2521
D3662
(2s,3s)-(+)-3-acetoxy-2,3-dihydro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one hydrochloride
cartia
CHEMBL1697
rg-83606
nsc-759576
taztia
dilt-cd
diltzac
HMS1568K10
cis-(1)-3-acetoxy-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one monohydrochloride
38411-61-9
einecs 253-918-0
AKOS015961992
diltia xt
dilt-xr
tiazac extended release
olh94387te ,
diltiazem hydrochloride [usan:usp:jan]
nsc 759576
unii-olh94387te
dodexen a.p.
presokin a. p.
dolizem
LP00327
dilthiazem hydrochloride
S1865
diltiazem hydrochloride [mart.]
diltiazem hydrochloride [ep impurity]
diltiazem hcl [vandf]
diltiazem hydrochloride [ep monograph]
diltiazem hydrochloride [jan]
diltiazem hydrochloride [usp-rs]
diltiazem hydrochloride [usp monograph]
diltiazem hydrochloride [mi]
diltiazem hydrochloride [who-dd]
diltiazem hydrochloride [usan]
diltiazem hydrochloride [vandf]
diltiazem hydrochloride [orange book]
CCG-220134
CCG-221631
diltiazem (hydrochloride)
HY-14656
HDRXZJPWHTXQRI-BHDTVMLSSA-N
cis-(+)-3-acetoxy-2,3-dihydro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one hydrochloride
NC00558
SCHEMBL15457
KS-5089
tox21_500327
NCGC00261012-01
(2s-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one hydrochloride
AC-32469
OPERA_ID_79
DTXSID8040147 ,
rg 83606 hcl
sr-01000075327
SR-01000075327-1
(2s,3s)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate hydrochloride
diltiazem hydrochloride, united states pharmacopeia (usp) reference standard
diltiazem hydrochloride, european pharmacopoeia (ep) reference standard
diltiazem hci
diltiazem for system suitability, european pharmacopoeia (ep) reference standard
diltiazem hydrochloride 1.0 mg/ml in acetonitrile (as free base)
J-019130
SR-01000003042-4
SR-01000003042-2
sr-01000003042
SW196487-3
(2s-trans)-diltiazem hydrochloride
[(2s,3s)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;hydrochloride
dilthiazem hcl
diltiazem, hydrochloride - cas 33286-22-5
(2s,3s)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate hcl
F20448
diltiazem hcl (tiazac)
diltiazem hydrochloride,(s)
acetate hydrochloride
tetrahydrobenzo[b][1,4]thiazepin-3-yl
(2s,3s)-5-(2-(dimethylamino)ethyl)-2
-(4-methoxyphenyl)-4-oxo-2,3,4,5-
Q27105183
(+)-cis-diltiazem hydrochloride, >/=98%
AS-13703
BCP13814
3,3,3-phosphinylidynetrispropionamide
AMY8835
[(2s,3s)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;hydron;chloride
33286-22-5 (hcl)
(+)-cis-diltiazem hydrochlorid
M01693
(2s,3s)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-ylacetatehydrochloride
diltiazem for system suitability
BD166408
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, hydrochloride (1:1), (2s,3s)-
EN300-123531
Z1551967090
diltiazem hydrochloride (ep impurity)
diltiazem hydrochloride (usp-rs)
diltiazem hydrochloride (usp monograph)
acetic acid (2s,3s)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo(b)(1,4)thiazepin-3-yl ester; hydrochloride
taztiaxt
diltiazem hydrochlorideextended-release
diltiazem hydrochloride extended-release tablets
dtxcid6020147
diltiazem hydrochloride (mart.)
diltiazem hcl cd
diltiazem hydrochlorideextended release
tiazacextended release
matzim la
(2s,3s)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate monohydrochloride
diltiazem hydrochloride extended-release
diltiazem hydrochloride (usan:usp:jan)
diltiazem hydrochloride extended release
(2s,3s)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate hydrochloride
diltiazem hydrochloride (ep monograph)
tiadylt er
diltiazem hydrochloride in dextrose 5%
diltiazem hcl er
cartiaxt
2-((2s,3s)-3-(acetyloxy)-2-(4-methoxyphenyl)-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2h)-yl)-n,n-dimethylethanaminium chloride
diltiazem.hcl
diltiazem.hcl, 1mg/ml in acetonitrile

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
calcium channel blockerOne of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485341
phosphopantetheinyl transferaseBacillus subtilisPotency70.79460.141337.9142100.0000AID1490
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.71220.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.34700.001530.607315,848.9004AID1224819; AID1224820; AID1224821
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16230.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.25120.540617.639296.1227AID2364; AID2528
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency2,511.88990.010039.53711,122.0200AID1479
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency16.15470.004611.374133.4983AID624296; AID624297
M-phase phosphoprotein 8Homo sapiens (human)Potency19.95260.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency18.30170.891312.067628.1838AID1459; AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID79656pA2 was measured as Calcium antagonistic activity 30 min after administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID59550Compound was tested for max increase in blood flow through cicumflex branch of left coronary artery, 60 min after administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID211999Lethal effect after per os administration in mouse for 7 days1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Organic phosphorus compounds. 5. (4-Benzothiazol-2-ylbenzyl)amidophosphonate as potent calcium antagonistic vasodilators.
AID60137Ability to increase coronary blood flow after intra duodenal administration at 3 mg/kg in dog; (SE +/- 23)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Organic phosphorus compounds. 5. (4-Benzothiazol-2-ylbenzyl)amidophosphonate as potent calcium antagonistic vasodilators.
AID56268Change in the heart rate and hypotensive action was measured in dogs at 10 mg/kg dose, 5 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56266Change in the heart rate and hypotensive action was measured in dogs at 10 mg/kg dose, 120 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID56269Change in the heart rate and hypotensive action was measured in dogs at 10 mg/kg dose, 60 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID55904Coronary vasodilatory activity as increase in coronary blood flow was determined in dogs after i.v. administration of the compound1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Organic phosphorus compounds. 5. (4-Benzothiazol-2-ylbenzyl)amidophosphonate as potent calcium antagonistic vasodilators.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID558030Drug concentration in human brain2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID60699Increasing effect on femoral blood flow (FBF) in femoral artery of anesthetized dogs.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
5-Isoquinolinesulfonamide derivatives. 1. Synthesis and vasodilatory activity of N-(2-guanidinoethyl)-5-isoquinolinesulfonamide derivatives.
AID59547Compound was tested for max increase in blood flow through cicumflex branch of left coronary artery, 120 min after administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56273Change in the mean blood pressure and hypotensive action was measured in dogs at 10 mg/kg dose, 60 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56272Change in the mean blood pressure and hypotensive action was measured in dogs at 10 mg/kg dose, 5 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID79483Calcium antagonistic activity in isolated guinea pig Tenia coli specimens; (SE +/- 0.06)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Organic phosphorus compounds. 5. (4-Benzothiazol-2-ylbenzyl)amidophosphonate as potent calcium antagonistic vasodilators.
AID747940Selectivity ratio of IC50 for rabbit CaV1.2alpha1C to IC50 for rat CaV1.3alpha1D2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease.
AID59548Compound was tested for max increase in blood flow through cicumflex branch of left coronary artery, 30 min after administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID59549Compound was tested for max increase in blood flow through cicumflex branch of left coronary artery, 5 min after administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56271Change in the mean blood pressure and hypotensive action was measured in dogs at 10 mg/kg dose, 30 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID134575LD50 value in mouse was calculated after the drug was administered intraperitoneally by Weil method1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID77144Maximum increase in coronary flow in isolated guinea pig heart at a dose of 10 ug.1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56270Change in the mean blood pressure and hypotensive action was measured in dogs at 10 mg/kg dose, 120 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID56267Change in the heart rate and hypotensive action was measured in dogs at 10 mg/kg dose, 30 min after id administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator.
AID558031Drug concentration in human plasma2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.90)18.7374
1990's3 (10.34)18.2507
2000's6 (20.69)29.6817
2010's16 (55.17)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.83 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index134.98 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (79.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.90%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (89.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]